文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-PSMA 11配体PET显像在前列腺根治术后生化复发患者中的诊断效能及对治疗决策的影响

68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-10-26

回顾性评估117例前列腺根治术后生化复发且未接受激素治疗的患者,行68Ga-PSMA 11 PET/CT或PET/MRI,并与单独CT/MRI比较。PSMA-PET在85.5%患者中检出阳性病灶,在CT/MRI按RECIST 1.1无可疑病灶的67例中检出病灶,并使其中74.6%的治疗决策发生改变。

要点

  • PSMA-PET在生化复发患者中检出病灶的总体阳性率为85.5%,PSA≥2 ng/ml时检出率达100%。
  • PSMA-PET在CT/MRI无可疑病灶的67例中检出病灶,并使其中74.6%的治疗决策改变。
  • PSMA-PET改变了治疗决策的患者中,86%被考虑接受转移灶定向治疗。

核心结论

  • PSMA-PET显像对前列腺根治术后生化复发患者的复发灶检出具有高效能,即使在相对较低的PSA水平也能检出。
  • PSMA-PET在标准CT/MRI基础上增加显著信息,使相当数量患者的治疗策略发生改变。

研究设计与样本

  • 回顾性评估117例前列腺根治术后生化复发且未接受激素治疗的患者,于2014年5月至2017年1月间行68Ga-PSMA 11 PET/CT(n=46)或PET/MRI(n=71)。
  • 生化复发定义为PSA两次升高超过0.2 ng/ml。
  • 两名泌尿肿瘤影像专家分别独立阅片,结果以盲法序贯方式提交多学科肿瘤委员会以评估对决策的影响。

主要发现

  • 从根治术到生化复发的中位时间为36个月(IQR 16-72),69例(59%)患者接受过术后放疗,显像时中位PSA为1.04 ng/ml(IQR 0.58-1.87)。
  • 100例(85.5%)患者检出PSMA阳性病灶;PSA 0.2至<0.5 ng/ml时检出率为65%,0.5至<1 ng/ml为85.7%,1至<2 ng/ml为85.7%,≥2 ng/ml为100%。
  • 79%患者的PSMA阳性病灶经组织学(16%)、转移灶定向放疗后PSA下降(45%)或PET/MRI扩散加权成像额外信息(18%)证实。
  • 67例(57.3%)患者在MRI或CT上按RECIST 1.1无可疑对应病灶,PSMA-PET在其中检出病灶。
  • PSMA-PET使这67例中74.6%的治疗决策发生改变(p < 0.001),其中86%被考虑接受转移灶定向治疗。

关键数值与推荐

  • 生化复发定义:PSA两次升高超过0.2 ng/ml。
  • PSA 0.2至<0.5 ng/ml时PSMA-PET检出率为65%。
  • PSA 0.5至<1 ng/ml时PSMA-PET检出率为85.7%。
  • PSA 1至<2 ng/ml时PSMA-PET检出率为85.7%。
  • PSA≥2 ng/ml时PSMA-PET检出率为100%。

临床怎么用

  • 作者确认PSMA-PET显像对前列腺根治术后生化复发患者的复发灶检出具有高效能,即使PSA水平相对较低。
  • 作者指出PSMA-PET在标准CT/MRI基础上增加显著信息,使相当数量患者的治疗策略发生改变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the diagnostic performance of [68Ga]Ga-PSMAHBED-CC conjugate 11 positron emission tomography (PSMA-PET) in the early detection of metastases in patients with biochemical recurrence (BCR) after radical prostatectomy (RP) for clinically non-metastatic prostate cancer, to compare it to CT/MRI alone and to assess its impact on further therapeutic decisions. MATERIAL AND METHODS: We retrospectively assessed 117 consecutive hormone-naïve BCR patients who had 68Ga-PSMA 11 PET/CT (n = 46) or PET/MRI (n = 71) between May 2014 and January 2017. BCR was defined as two PSA rises above 0.2 ng/ml. Two dedicated uro-oncological imaging experts (radiology/nuclear medicine) reviewed separately all images. All results were presented in a blinded sequential fashion to a multidisciplinary tumorboard in order to assess the influence of PSMA-PET imaging on decision-making. RESULTS: The median time from RP to BCR was 36 months (IQR 16-72). Overall, 69 (59%) patients received postoperative radiotherapy. Median PSA level at the time of imaging was 1.04 ng/ml (IQR 0.58-1.87). PSMA-positive lesions were detected in 100 (85.5%) patients. Detection rates were 65% for a PSA value of 0.2 to <0.5 ng/ml, 85.7% for 0.5 to <1, 85.7% for 1 to <2 and 100% for ≥2. PSMA-positive lesions could be confirmed by either histology (16%), PSA decrease in metastasis-directed radiotherapy (45%) or additional information in diffusion-weighted imaging when PET/MRI was performed (18%) in 79% of patients. PSMA-PET detected lesions in 67 patients (57.3%) who had no suspicious correlates according to the RECIST 1.1 criteria on MRI or CT. PSMA-PET changed therapeutic decisions in 74.6% of these 67 patients (p < 0.001), with 86% of them being considered for metastases-directed therapies. CONCLUSIONS: We confirm the high performance of PSMA-PET imaging for the detection of disease recurrence sites in patients with BCR after RP, even at relatively low PSA levels. Moreover, it adds significant information to standard CT/MRI, changing treatment strategies in a significant number of patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Grubmüller B, Baltzer P, D'Andrea D, et al. 68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making. Eur J Nucl Med Mol Imaging. 2017. PMID: 29075832. doi:10.1007/s00259-017-3858-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。